Financings in Brief: CardioTech International
This article was originally published in The Gray Sheet
Executive Summary
CardioTech International: Shares of the former PolyMedica Industries unit begin trading June 12 on the American Stock Exchange. PolyMedica announced in March its plans to spin off more than 90% of outstanding shares in CardioTech to its shareholders. On June 11, PolyMedica shareholders received 0.42832 shares of CardioTech, a Woburn, Massachusetts-based developer of vascular grafts, for each PolyMedica share held. In accordance with the terms of the spin-off and due to the average trading price of CardioTech stock during its first five trading days, PolyMedica shareholders will receive an additional 0.05383 per share on June 27, 1996. The spin-off "affords both PolyMedica and CardioTech greater access to the capital markets by permitting the two companies to be evaluated independently by the financial community," PolyMedica says...
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.